Pharmacokinetics and clinical response to single agent rucaparib in a dialysis dependent patient with BRCA associated breast and recurrent ovarian cancer

A 56-year old woman with BRCA-associated breast cancer and recurrent ovarian cancer was treated with a poly (ADP-ribose) polymerase enzyme (PARP) inhibitor, rucaparib, in the setting of dialysis-dependence which required dose modification. Rucaparib trough levels were obtained before and after dialy...

Descripción completa

Detalles Bibliográficos
Autores principales: Harold, Justin A., Free, Stephanie C., Bradley, William H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223187/
https://www.ncbi.nlm.nih.gov/pubmed/30426062
http://dx.doi.org/10.1016/j.gore.2018.10.011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223187/
https://www.ncbi.nlm.nih.gov/pubmed/30426062
http://dx.doi.org/10.1016/j.gore.2018.10.011

Ejemplares similares